Identifying the right treatment for each patient relies on biomarker testing. Partnering with ABC Global Alliance, we conducted a global study to understand the challenges people with metastatic breast cancer face when learning about their biomarkers. Learn how new treatment approaches and clear information can improve patient experience: https://learn.az/6041gBOoP
Hi AZ and ABC, I wonder if the confusion felt by the patient in regards to biomarkers is a result of the pathologists+oncologists themselves feeling overwhelmed and inundated with the flood of new biomarkers hitting the market. At least that is our interpretation of the situation. This is highlighted in the below graphic, if you think this looks confusing, you should see what the data looks like for NSCLC.
I have a suggestion: a cancer metastasis marker. https://pubmed.ncbi.nlm.nih.gov/29096248/
Understanding patient perspectives on biomarker testing is crucial for personalized treatment in metastatic breast cancer. Looking forward to learning more about the study findings with ABC Global Alliance!
Arby Leonian I hope you're well! I think you may find this report interesting!
Great research and thanks to AstraZeneca !
Thank you for driving this essential research forward!